Assembly Biosciences

ASMB · Nasdaq · United States

Share price · ASMB

$22.39-9.74 (-30.31%) 3M

close as of 2026-11-18 · 24h delayed · vol 487K (1.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ASMB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026+5.7%
  2. 12 Nov 2026-9.8%
  3. 13 Oct 2026-10.7%

    Nothing announced by ASMB that day or the session before.

  4. 15 Sep 2026-9.8%

    Nothing announced by ASMB that day or the session before.

  5. 17 Aug 2026-8.9%
  6. 14 Aug 2026+10.0%
  7. 13 Aug 2026+10.7%
  8. 26 Jun 2026+10.2%

    Nothing announced by ASMB that day or the session before.

  9. 25 Jun 2026-5.3%

    Nothing announced by ASMB that day or the session before.

  10. 24 Jun 2026-4.4%

    Nothing announced by ASMB that day or the session before.

Share of unusual movement by asset

For each asset, the share of ASMB's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—79%

No dated announcements about its assets since 3 Sep 2025.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
HSV helicase-primase complexSmall molecule
Herpes Simplex Virus Infection
Genital Herpes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$3.0M$20M$29M+ $285M short-term inv.$20M-$17M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$13M$15M$32M+ $288M short-term inv.$3.9M-$15M operating cash flowreport ↗
2026-Q1$8.2M$15M$31M+ $195M short-term inv.$9.1M-$22M operating cash flowreport ↗
2025-Q3$11M$17M$23M+ $210M short-term inv.$9.2M-$15M operating cash flowreport ↗
2025-Q2$9.6M$16M$24M+ $51M short-term inv.$10M-$17M operating cash flowreport ↗
2025-Q1$9.4M$15M$23M+ $68M short-term inv.$8.8M-$23M operating cash flowreport ↗
2024-Q3$6.8M$14M$28M+ $67M short-term inv.$9.6M-$15M operating cash flowreport ↗
2024-Q2$8.5M$16M$19M+ $90M short-term inv.$11M-$17M operating cash flowreport ↗
2024-Q1$5.8M$12M$19M+ $94M short-term inv.$9.1M-$18M operating cash flowreport ↗
2023-Q3$0$11M$27M+ $20M short-term inv.$14M-$14M operating cash flowreport ↗
2023-Q2$0$13M$22M+ $38M short-term inv.$17M-$14M operating cash flowreport ↗
2023-Q1$0$15M$43M+ $30M short-term inv.$19M-$23M operating cash flowreport ↗
2022-Q3—$18M$55M+ $54M short-term inv.$23M-$20M operating cash flowreport ↗
2022-Q2—$18M$43M+ $74M short-term inv.$24M-$18M operating cash flowreport ↗
2022-Q1—$17M$51M+ $72M short-term inv.$23M-$28M operating cash flowreport ↗
2021-Q3$6.3M$18M$71M+ $110M short-term inv.$19M-$19M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$65M$58M+ $190M short-term inv.$1.5M-$41M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$29M$56M$38M+ $74M short-term inv.$10M-$51M operating cash flowreport ↗
2023-FY$7.2M$49M$20M+ $110M short-term inv.$15M$23M operating cash flowreport ↗
2022-FY$0$70M$52M+ $39M short-term inv.$23M-$84M operating cash flowreport ↗
2021-FY$6.3M$69M$46M+ $101M short-term inv.$32M-$93M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($252K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Okazaki Jason A · director, CEO and PresidentOpen-market sale6,133$19.61$120KForm 4
2026-11-02Gaggar Anuj · Chief Medical OfficerOpen-market sale2,564$19.61$50KForm 4
2026-11-02White Nicole S · Chief Manufacturing OfficerOpen-market sale2,564$19.61$50KForm 4
2026-11-02Bjorkquist Jeanette M · PFO and PAOOpen-market sale718$19.61$14KForm 4
2026-11-02Okazaki Jason A · director, CEO and PresidentOpen-market sale69$20.35$1KForm 4
2026-11-02Gaggar Anuj · Chief Medical OfficerOpen-market sale29$20.35$590Form 4
2026-11-02White Nicole S · Chief Manufacturing OfficerOpen-market sale29$20.35$590Form 4
2026-11-02Bjorkquist Jeanette M · PFO and PAOOpen-market sale9$20.35$183Form 4